Ischemic stroke: a paradoxical manifestation of cancer

Vista sencilla de ítem
dc.contributor.authorSalazar-Camelo, Ruth A.
dc.contributor.authorMoreno-Vargas, Eder A.
dc.contributor.authorCardona-Mendoza, Andrés Felipe
dc.contributor.authorBayona-Ortiz, Hernán F.
dc.contributor.orcidCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.date.accessioned2021-01-28T20:02:58Z
dc.date.available2021-01-28T20:02:58Z
dc.date.issued2021
dc.description.abstractenglishIntroduction: Approximately 5–10 % of the patients with cryptogenic stroke have an underlying malignancy. Stroke as a complication of cancer increases the morbidity and mortality among cancer patients, leading to increased disability and healthcare costs. Objective: To provide elements to guide physicians for when to suspect and evaluate for cancer in stroke patients. Development: We performed a narrative review, portrayed in a question-answer format, to report relevant aspects of cancer stroke patients in the clinical practice and provide a guide based on the state-of-the-art literature. Conventional stroke mechanisms are only found in a fraction of patients with cancer. Although cardiovascular risk factors play an important role in both cancer and stroke pathogenesis, the recognition of more specific cancer-associated risk factors raises clinical suspicion for occult malignancy. We also expose the main type location and histology of tumors that are most commonly associated with stroke as well as potential blood biomarkers and current treatment considerations in the scenario of cancer associated stroke. Conclusion: Subjects with active cancer are a patient population at increased risk for developing an ischemic stroke. Cryptogenic stroke patients have a higher risk of cancer diagnosis in the following 6–12 months. We recommend a multidisciplinary approach considering the high probability of a hidden malignancy and running a comprehensive evaluation including neurologic imaging, serological biomarkers and tight follow up.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.critrevonc.2020.103181
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1040-8428
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/5217
dc.language.isoeng
dc.publisherElsevierspa
dc.publisher.journalCritical reviews in oncology/hematologyspa
dc.relation.ispartofseriesCritical reviews in oncology/hematology, 1040-8428, Vol. 157spa
dc.relation.urihttps://www.sciencedirect.com/science/article/pii/S1040842820303176?via%3Dihub
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2021-01
dc.rights.localAcceso abiertospa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.keywordsCancerspa
dc.subject.keywordsHypercoagulabilityspa
dc.subject.keywordsMortalityspa
dc.subject.keywordsPrognosisspa
dc.subject.keywordsRisk factorsspa
dc.subject.keywordsStrokespa
dc.titleIschemic stroke: a paradoxical manifestation of cancerspa
dc.title.translatedIschemic stroke: a paradoxical manifestation of cancerspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Salazar-Camelo, R.A., Moreno-Vargas, E.A_2021.pdf
Tamaño:
3.61 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos